{"TopicDetails": {"type": 0, "ccm2Id": 31069760, "cftId": 0, "identifier": "IMI2-2015-05-02", "title": "Diabetic Kidney Disease Biomarkers (DKD-BM)", "publicationDateLong": 1436400000000, "callIdentifier": "H2020-JTI-IMI2-2015-05-two-stage", "callTitle": "H2020-JTI-IMI2-2015-05-two-stage", "callccm2Id": 31069647, "frameworkProgramme": {"id": 31045243, "abbreviation": "H2020", "description": "Horizon 2020"}, "programmeDivision": [{"id": 31047894, "abbreviation": "EU.3.1.", "description": "Health, demographic change and wellbeing"}, {"id": 31062059, "abbreviation": "EU.3.1.7.", "description": "Innovative Medicines Initiative 2 (IMI2)"}, {"id": 31045244, "abbreviation": "EC", "description": "EC Treaty"}, {"id": 31047893, "abbreviation": "EU.3.", "description": "Societal Challenges"}], "sme": false, "actions": [{"status": {"id": 31094503, "abbreviation": "Closed", "description": "Closed"}, "types": ["IMI2-RIA Research and Innovation action"], "plannedOpeningDate": "09 July 2015", "submissionProcedure": {"id": 31094505, "abbreviation": "two-stage", "description": "two-stage"}, "deadlineDates": ["13 October 2015", "15 March 2016"]}], "latestInfos": [], "budgetOverviewJSONItem": {"budgetTopicActionMap": {"3201028": [{"action": "IMI2-2015-05-03 - IMI2-RIA Research and Innovation action", "plannedOpeningDate": "09 July 2015", "deadlineModel": "two-stage", "deadlineDates": ["13 October 2015", "15 March 2016"], "budgetYearMap": {"2015": 8600000}, "budgetTopicActionMap": {}}], "3201029": [{"action": "IMI2-2015-05-04 - IMI2-RIA Research and Innovation action", "plannedOpeningDate": "09 July 2015", "deadlineModel": "two-stage", "deadlineDates": ["13 October 2015", "15 March 2016"], "budgetYearMap": {"2015": 12000000}, "budgetTopicActionMap": {}}], "3201030": [{"action": "IMI2-2015-05-01 - IMI2-RIA Research and Innovation action", "plannedOpeningDate": "09 July 2015", "deadlineModel": "two-stage", "deadlineDates": ["13 October 2015", "15 March 2016"], "budgetYearMap": {"2015": 5600000}, "budgetTopicActionMap": {}}], "3201031": [{"action": "IMI2-2015-05-06 - IMI2-RIA Research and Innovation action", "plannedOpeningDate": "09 July 2015", "deadlineModel": "two-stage", "deadlineDates": ["13 October 2015", "15 March 2016"], "budgetYearMap": {"2015": 2640000}, "budgetTopicActionMap": {}}], "3201032": [{"action": "IMI2-2015-05-02 - IMI2-RIA Research and Innovation action", "plannedOpeningDate": "09 July 2015", "deadlineModel": "two-stage", "deadlineDates": ["13 October 2015", "15 March 2016"], "budgetYearMap": {"2015": 14900000}, "budgetTopicActionMap": {}}], "3201033": [{"action": "IMI2-2015-05-05 - IMI2-RIA Research and Innovation action", "plannedOpeningDate": "09 July 2015", "deadlineModel": "two-stage", "deadlineDates": ["13 October 2015", "15 March 2016"], "budgetYearMap": {"2015": 2043000}, "budgetTopicActionMap": {}}]}, "budgetYearsColumns": ["2015"]}, "description": "<SPAN class=\"topicdescriptionkind\">Specific Challenge</SPAN>:<p>Worldwide, diabetic kidney disease (DKD) is the leading cause of end stage renal disease (ESRD), and its global incidence and prevalence are increasing. The 5-year survival of a dialysis patient with DKD is less than 25 percent\u2014worse than most cancers\u2014new treatments are desperately needed to slow and/or reverse disease in this high-risk patient population. In order for DKD trials to be more successful in the future, the research community will need to advance a concerted effort to identify personalized markers to identify patients at high risk of progression, to identify patient subpopulations that are likely to respond to candidate therapeutics and to provide early indications of potential safety issues linked to candidate therapeutic agents.</p>\n<SPAN class=\"topicdescriptionkind\">Scope</SPAN>:<p>The objectives are to identify and validate candidate biomarkers and/or biomarker panels from existing longitudinal databases. Enhance the understanding of key driver pathways that accelerate progression of DKD, as well as pathways that enable &amp; drive the pathogenesis of DKD in the overall context of diabetes itself. Asses differences between DKD associated with Type 1 DM and Type 2 DM. In parallel with this early work in biomarker identification and profiling of people with DKD, preclinical efforts will leverage longitudinal clinical database findings to identify better in vitro and in vivo models of DKD, identify predictive biomarkers for both efficacy and safety, and identify new druggable target pathways for future drug development. The overarching goal is to provide therapeutic developers with new tools that are acceptable to global regulators to enable and facilitate drug development (e.g. companion diagnostics).</p>\n<SPAN class=\"topicdescriptionkind\">Expected Impact</SPAN>:<p>The overall Project is expected to significantly advance the understanding of the pathophysiology, heterogeneity and natural history of DKD in patients, improve the knowledge on translatable preclinical models for DKD, and facilitate the development of standardized biomarker panels with both prognostic and predictive capacity to serve as entry criteria for future clinical trial protocols evaluating novel therapies for DKD.</p>\n", "conditions": "<p>Please read carefully all provisions below before the preparation of your application.</p>\r\n<p><em>The <strong><span style=\"color: #003366\">budget breakdown </span></strong>for this call is given&nbsp;at the end of&nbsp;the Call&nbsp;topics text&nbsp;in the&nbsp;<a href=\"http://ec.europa.eu/research/participants/data/ref/h2020/other/call_fiches/jtis/h2020-call-fiche15-5-imi2-ju_en.pdf\"><strong>Call Conditions</strong>&nbsp;</a>section, as well as the following information:</em></p>\r\n<ol>\r\n    <li><strong><span style=\"color: rgb(0,51,102)\">List of countries and applicable rules for funding</span></strong><br />\r\n    &nbsp;</li>\r\n    <li><strong><span style=\"color: rgb(0,51,102)\">Eligibility and admissibility conditions</span></strong><br />\r\n    &nbsp;</li>\r\n    <li><strong><span style=\"color: rgb(0,51,102)\">Evaluation</span></strong><strong><span style=\"color: rgb(0,51,102)\">&nbsp;criteria and procedure, scoring and threshold:</span></strong> described in <a href=\"http://ec.europa.eu/research/participants/data/ref/h2020/other/guides_for_applicants/jtis/h2020-guide-pse-imi-ju_en.pdf\"><strong>IMI2</strong> Manual for submission, evaluation and grant award</a><br />\r\n    &nbsp;</li>\r\n    <li><strong style=\"color: rgb(0,51,102)\">Indicative timetable for evaluation and grant agreement</strong> <br />\r\n    &nbsp;</li>\r\n    <li><strong><span style=\"color: rgb(0,51,102)\">Provisions, proposal templates and evaluation forms for the type(s) of action(s) under this topic: </span></strong><br />\r\n    <br />\r\n    <u>Research and Innovation Action:</u><br />\r\n    <br />\r\n    IMI2 Research and Innovation Action (IMI2-RIA) and (IMI2-IA):<br />\r\n    <br />\r\n    <a href=\"http://ec.europa.eu/research/participants/data/ref/h2020/other/guide-appl/jti/h2020-guide-pse-imi-ju_en.pdf\">Summary of the most relevant provisions for participating in IMI2 actions</a><br />\r\n    <a href=\"http://ec.europa.eu/research/participants/data/ref/h2020/other/call_ptef/pt/h2020-call-pt-imi2-ria_en.pdf\">Standard proposal template</a><br />\r\n    <a href=\"http://ec.europa.eu/research/participants/data/ref/h2020/other/call_ptef/ef/h2020-call-ef-imi2-ria_en.pdf\">Standard Evaluation&nbsp;form</a><br />\r\n    <a href=\"http://ec.europa.eu/research/participants/data/ref/h2020/other/mga/jti/h2020-mga-imi_en.pdf\">IMI2&nbsp;Model Grant Agreement&nbsp;</a><br />\r\n    <br />\r\n    &nbsp;</li>\r\n</ol>", "supportInfo": "<p>&nbsp;</p>\r\n<ul>\r\n    <li>Contact the <strong>IMI Programme Office</strong>. E-mail: <a href=\"mailto:Infodesk@imi.europa.eu\">Infodesk@imi.europa.eu</a>. Tel.: +32 2 221 8181</li>\r\n    <li>Contact the <a href=\"mailto:sofia@imi.europa.eu\">SOFIA IT helpdesk </a>for questions such as forgotten passwords, access rights and roles, technical aspects of submission of proposals, etc.</li>\r\n    <li><a href=\"http://www.imi.europa.eu/content/states-representatives-groups\">IMI States Representative Group (SRG) </a>&ndash; contact your SRG member for assistance</li>\r\n    <li><a href=\"http://www.imi.europa.eu/content/partner-search\">IMI Partner Search Tool </a>- find a partner organisation for your proposal</li>\r\n    <li><a href=\"http://ec.europa.eu/research/participants/portal/desktop/en/support/national_contact_points.html\">National Contact Points (NCP)</a> &ndash; contact your NCP for further assistance</li>\r\n    <li><a href=\"http://een.ec.europa.eu/\">Enterprise Europe Network </a>&ndash; contact your EEN national contact for advice to businesses with special focus on SMEs. The support includes guidance on the EU research funding</li>\r\n    <li><a href=\"http://ec.europa.eu/research/index.cfm?lg=en&amp;pg=enquiries\">Research Enquiry Service </a>&ndash; ask questions about any aspect of European research in general and the EU Research Framework Programmes in particular</li>\r\n    <li><strong>Ethics </strong>&ndash; to ensure compliance with ethical issues, check the information available on the <a href=\"http://ec.europa.eu/research/participants/docs/h2020-funding-guide/cross-cutting-issues/ethics_en.htm\">Participant Portal</a>, on the <a href=\"http://ec.europa.eu/research/swafs/index.cfm?pg=policy&amp;lib=ethics\">Science and Society Portal </a>and in <a href=\"http://ec.europa.eu/euraxess/pdf/brochure_rights/am509774CEE_EN_E4.pdf\">The European Charter for Researchers and the Code of Conduct for their recruitment </a></li>\r\n    <li><a href=\"http://www.cencenelec.eu/research/pages/default.aspx\">CEN </a>and <a href=\"http://www.cenelec.eu/aboutcenelec/whatwestandfor/fosterinnovation/randd.html\">CENELEC</a>, the European Standards Organisations, <strong>advise you how to tackle standardisation in your project proposal</strong>. Contact the CEN-CENELEC Research Helpdesk at <a href=\"mailto:research@cencenelec.eu\">research@cencenelec.eu </a></li>\r\n</ul>\r\n<p><br />\r\n.</p>", "sepTemplate": "<p>To access the Electronic Submission Service of the topic, please select the <strong>type of action</strong> that is most relevant to your proposal from the list below and click on the <strong>'Start Submission' </strong>button. You will then be asked to confirm your choice of the type of action, the topic for the call, as these cannot be changed subsequently in the submission system. Upon confirmation you will be linked to the correct entry point.</p>\r\n<p>To access existing draft proposals for this topic, please login to the Participant Portal and select the My Proposals page of the My Area section.</p>", "links": [{"callIdentifier": "H2020-JTI-IMI2-2015-05-two-stage-Master-1", "status": "Closed", "criterionType": "SubFundingScheme", "criterionTypeDescription": "subfunding schemes", "criterionCode": "IMI2-RIA", "criterionDescription": "Research and Innovation action", "url": "https://sofia.imi.europa.eu/Pages/Default.aspx", "startDate": "Jul 9, 2015 11:00:00 AM"}], "additionalDossiers": [], "infoPackDossiers": [{"callId": 6791, "id": 9295, "title": "IMI2 Call 5 topics text", "sectionId": 6791, "translationFiles": [{"language": "en", "mimeType": "application/pdf", "fileSize": 507719, "docPath": "http://ec.europa.eu/research/participants/portal/doc/call/h2020/imi2-2015-05-02/1662621-c5_imi2_c5_text_9_july_2015_en.pdf", "id": 1662621, "fileName": "C5_IMI2_C5_TEXT_9 JULY 2015_EN.pdf", "common": false, "crc32": 3363543276}]}, {"callId": 6791, "id": 9290, "title": "IMI2 RIA-IA Evaluation Form ", "sectionId": 6791, "translationFiles": [{"language": "en", "mimeType": "application/pdf", "fileSize": 97244, "docPath": "http://ec.europa.eu/research/participants/portal/doc/call/h2020/imi2-2015-05-02/1662622-c5_evaluation-form_ria-ia_en.pdf", "id": 1662622, "fileName": "C5_Evaluation-Form_RIA-IA_EN.pdf", "common": false, "crc32": 4124235812}]}, {"callId": 6791, "id": 9280, "title": "IMI2 RIA-IA Proposal Template", "sectionId": 6791, "translationFiles": [{"language": "en", "mimeType": "application/pdf", "fileSize": 184629, "docPath": "http://ec.europa.eu/research/participants/portal/doc/call/h2020/imi2-2015-05-02/1662623-c5_proposal-template_ria-ia_en.pdf", "id": 1662623, "fileName": "C5_Proposal-Template_RIA-IA_EN.pdf", "common": false, "crc32": 3554732561}]}, {"callId": 6791, "id": 9275, "title": "IMI2 Manual for Submission, Evaluation and Grant Award", "sectionId": 6791, "translationFiles": [{"language": "en", "mimeType": "application/pdf", "fileSize": 546419, "docPath": "http://ec.europa.eu/research/participants/portal/doc/call/h2020/imi2-2015-05-02/1662624-c5_manual_for_subission-evaluation_and_grant_award_en.pdf", "id": 1662624, "fileName": "C5_MANUAL FOR SUBISSION-EVALUATION AND GRANT AWARD_EN.pdf", "common": false, "crc32": 1572805413}]}, {"callId": 6791, "id": 9270, "title": "Summary of the most relevant provisions for participating in IMI2 actions", "sectionId": 6791, "translationFiles": [{"language": "en", "mimeType": "application/pdf", "fileSize": 177193, "docPath": "http://ec.europa.eu/research/participants/portal/doc/call/h2020/imi2-2015-05-02/1662625-c5_summary_of_the_most_relevant_provisions_for_participating_in_imi2_actions_en.pdf", "id": 1662625, "fileName": "C5_Summary of the most relevant provisions for participating in IMI2 actions_EN.pdf", "common": false, "crc32": 1929684055}]}, {"callId": 6791, "id": 9285, "title": "IMI2 Model Grant Agreement", "sectionId": 6791, "translationFiles": [{"language": "en", "mimeType": "application/pdf", "fileSize": 1209392, "docPath": "http://ec.europa.eu/research/participants/portal/doc/call/h2020/imi2-2015-05-02/1662626-c5_imi2_model_grand_agreement_en.pdf", "id": 1662626, "fileName": "C5_IMI2 MODEL GRAND AGREEMENT_EN.pdf", "common": false, "crc32": 1198578495}]}], "callDetailsJSONItem": {"additionalInfo": "<p>For full information on this call, please refer to the <a href=\"http://www.imi.europa.eu/content/imi-2-call-5-0\">Call&nbsp;5 section of the IMI website</a>.</p>\r\n<p>Please note that submitting short proposals for this call can only be done through the <a href=\"https://sofia.imi.europa.eu/Pages/Login.aspx?ReturnUrl=%2fPages%2fDefault.aspx\">IMI SOFIA software tool</a></p>", "latestInfos": [{"approvalDate": "Sep 23, 2015 11:02:51 AM", "lastChangeDate": "Sep 23, 2015 11:02:24 AM", "content": "<p><span style=\"color: #ff0000\">Update!</span> The European Medicines Agency (EMA) is willing to join the selected applicant consortium for the full proposal submission (stage two) of the topic 'Patient perspective elicitation on benefits and risks of medicinal products, from development through the entire life cycle, to inform the decision-making process by regulators and health technology assessment bodies' together with the industry consortium. The proposed EMA contribution can be found here (and on the IMI web site) for consideration by the applicant consortia. The EMA will cover its own participation costs. For more information please contact the IMI Infodesk (infodesk@imi.europa.eu) and/or the EMA (henry.fitt@ema.europa.eu).<br />\r\n&nbsp;</p>"}, {"approvalDate": "Jul 10, 2015 7:07:58 PM", "lastChangeDate": "Jul 10, 2015 7:07:58 PM", "content": "The submission session is now available for: H2020-JTI-IMI2-2015-05-01(IMI2-RIA), H2020-JTI-IMI2-2015-05-02(IMI2-RIA), H2020-JTI-IMI2-2015-05-03(IMI2-RIA), H2020-JTI-IMI2-2015-05-04(IMI2-RIA), H2020-JTI-IMI2-2015-05-05(IMI2-RIA), H2020-JTI-IMI2-2015-05-06(IMI2-RIA)"}], "hasForthcomingTopics": false, "hasOpenTopics": false, "allClosedTopics": true}}}